암배아항원(CEA) 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the carcinoembryonic antigen (CEA) market size is expected to increase from USD 2.17 billion in 2025 to USD 2.31 billion in 2026 and reach USD 3.12 billion by 2031, growing at a CAGR of 6.24% over 2026-2031.

This report is Segmented by Product (Assay Kits, Analyzers/Instruments, Consumables & Reagents), Application (Colorectal Cancer, Pancreatic Cancer, Lung Cancer, Breast Cancer, and More), End User (Hospitals & Surgical Centers, Diagnostic Laboratories, Academic & Research Institutes, Others), and Geography (North America and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Carcinoembryonic Antigen (CEA) Market Trends and Insights

Escalating Global Colorectal Cancer Prevalence

Rising colorectal cancer incidence is a structural growth catalyst for the CEA market. China alone reported about 4.8 million new cancer cases in 2022, with colorectal malignancies among the top contributors Lifestyle shifts toward Western diets, ageing populations, and improved detection are enlarging the addressable patient pool across Asia-Pacific and North America. Healthcare systems now embed CEA measurement into routine surveillance, as seen in Thailand's two-step FIT-plus-CEA program that feeds patients into colonoscopy pathways . Clinicians value CEA for its 80% sensitivity in identifying liver metastases, reinforcing its role in longitudinal monitoring . As screening participation rises, test volumes-and thus consumable pull-through-scale proportionally. This dynamic sustains baseline growth even when adoption of competing genomic tools accelerates.

Shift Toward Minimally-Invasive Biomarker-Based Monitoring

Physicians show mounting preference for blood-based assays that lower procedural burden while sustaining diagnostic accuracy. The FDA approval of the Shield test in 2024, which detects colorectal cancer with 83% sensitivity, exemplifies this non-invasive trend . Capillary-blood micro-collection devices now match venous-draw accuracy, enabling frequent outpatient testing without phlebotomy queues. Post-operative surveillance protocols increasingly replace imaging with serial CEA measurement, reducing patient exposure to radiation and cost. Patient adherence improves materially when follow-up requires a finger-stick rather than a colonoscopy, and AI algorithms that analyze CEA trajectories are further elevating clinical confidence. These factors collectively widen the clinical window for early intervention and reinforce recurring reagent demand.

Limited Specificity of CEA Leading to False Positives

Despite ubiquity, CEA suffers non-malignant elevation in smokers, diabetics, and patients with benign polyps, producing false-positive rates as high as 99.5% within the 5.1-10 ng/mL band [KAMJE.ORG]. In routine surveillance, nearly half of colorectal cancer survivors record sporadic CEA spikes unrelated to relapse, driving unnecessary imaging and patient anxiety.

Laboratories therefore adopt reflex testing algorithms that delay clinical action until sequential rises are confirmed, but this lengthens turnaround and raises cost. The specificity shortfall limits CEA utility in population screening, confining its core value to treatment monitoring. Research now orients toward multi-analyte models that blend CEA with ctDNA or proteomic signatures to mitigate erroneous positives.

Other drivers and restraints analyzed in the detailed report include:

1. Technological Advances in High-Sensitivity Multiplex Immunoassays
2. Expanding Government-Funded Cancer Screening Programs in Asia-Pacific
3. Competition from Emerging Genomic & Proteomic Biomarkers

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Assay kits commanded 45.62% market share in 2025, reflecting their central role in standardizing CEA testing across diverse laboratory environments. The dominance of assay kits stems from their comprehensive nature, providing complete testing solutions that ensure reproducibility and regulatory compliance across different healthcare settings. However, the consumables and reagents segment is projected to grow at 7.21% CAGR through 2031, driven by increasing test volumes and the recurring revenue model inherent in consumables. Analyzers and instruments represent the smallest segment but provide the technological foundation for high-throughput CEA testing, with companies like BD launching advanced platforms such as the FACSDiscover A8 Cell Analyzer featuring breakthrough spectral and real-time imaging technologies.

The shift toward automation and high-throughput testing is reshaping product demand patterns, with Siemens Healthineers focusing on human-centered engineering in laboratory automation to enhance diagnostic workflows and reduce manual intervention requirements . Point-of-care testing platforms are emerging as a disruptive force, with bioMerieux's acquisition of SpinChip Diagnostics in January 2025 bringing immunoassay technology that delivers results from whole blood samples in 10 minutes. This technological evolution is creating new product categories that blur traditional boundaries between assay kits, instruments, and consumables, as integrated platforms offer complete testing solutions with minimal user intervention.

Geography Analysis

North America's 41.86% revenue share in 2025 underscores deep integration of companion diagnostics, generous insurance coverage, and robust oncology infrastructures. The United States benefits from Medicare reimbursement for CEA monitoring in resected colorectal cancer, while the FDA fast-tracks innovative assays, sustaining technology refresh cycles . Consolidation among private payers pressures laboratories on pricing, yet elevated test volumes keep aggregate revenues stable. Canada and Mexico contribute incremental growth through national screening roll-outs and cross-border reference-lab collaborations.

Asia-Pacific delivers the fastest 6.82% CAGR and will add sizeable absolute value to the CEA market by 2031. China funds multi-cancer screening pilots incorporating blood-based biomarkers, with provincial programs purchasing bulk assay lots under centralized tenders. Japan's biennial endoscopy plus biomarker monitoring regimen drives sustained kit consumption. India's AI-augmented oncology diagnostics ecosystem blends affordable multiplex assays with cloud analytics, widening rural access and lifting reagent demand.

Europe shows steady single-digit growth via harmonized health-technology assessment pathways that endorse CEA for surveillance rather than screening. National Health Services negotiate volume-based discounts, nudging vendors toward value-based contracting. South America and the Middle East & Africa remain nascent but promising: improving cancer registries and donor-funded screening pilots will gradually pull CEA test orders upward. Collectively, regional heterogeneity balances the global CEA market, with high-growth emerging markets offsetting mature-region price erosion.

1. Abbott Laboratories
2. Roche
3. Thermo Fisher Scientific
4. Siemens Healthineers
5. Danaher
6. Beckton Dickinson
7. bioMerieux
8. DiaSorin
9. Merck
10. Bio-Rad Laboratories
11. Tosoh
12. Fujirebio Diagnostics (H.U. Group)
13. Sysmex
14. Randox Laboratories
15. Quanterix Corporation
16. Creative Diagnostics
17. LabCorp
18. Quest Diagnostics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Escalating global colorectal cancer prevalence
  • 4.2.2 Shift toward minimally-invasive biomarker-based monitoring
  • 4.2.3 Technological advances in high-sensitivity multiplex immunoassays
  • 4.2.4 Expanding government-funded cancer screening programs in Asia-Pacific
  • 4.2.5 Rising demand for companion diagnostics in biologics trials
• 4.3 Market Restraints
  • 4.3.1 Limited specificity of CEA leading to false positives
  • 4.3.2 Competition from emerging genomic & proteomic biomarkers
  • 4.3.3 Pricing pressure from assay commoditization
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Product (Value)
  • 5.1.1 Assay Kits
  • 5.1.2 Analyzers / Instruments
  • 5.1.3 Consumables & Reagents
• 5.2 By Application (Value)
  • 5.2.1 Colorectal Cancer
  • 5.2.2 Pancreatic Cancer
  • 5.2.3 Lung Cancer
  • 5.2.4 Breast Cancer
  • 5.2.5 Liver Cancer
  • 5.2.6 Others
• 5.3 By End User (Value)
  • 5.3.1 Hospitals & Surgical Centers
  • 5.3.2 Diagnostic Laboratories
  • 5.3.3 Academic & Research Institutes
  • 5.3.4 Others
• 5.4 By Geography (Value)
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 India
    • 5.4.3.3 Japan
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 South America
    • 5.4.4.1 Brazil
    • 5.4.4.2 Argentina
    • 5.4.4.3 Rest of South America
  • 5.4.5 Middle East and Africa
    • 5.4.5.1 GCC
    • 5.4.5.2 South Africa
    • 5.4.5.3 Rest of Middle East and Africa

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 F. Hoffmann-La Roche Ltd
  • 6.3.3 Thermo Fisher Scientific Inc.
  • 6.3.4 Siemens Healthineers AG
  • 6.3.5 Danaher Corporation (Beckman Coulter)
  • 6.3.6 Becton, Dickinson and Company
  • 6.3.7 bioMerieux SA
  • 6.3.8 DiaSorin S.p.A.
  • 6.3.9 Merck KGaA
  • 6.3.10 Bio-Rad Laboratories, Inc.
  • 6.3.11 Tosoh Corporation
  • 6.3.12 Fujirebio Diagnostics (H.U. Group)
  • 6.3.13 Sysmex Corporation
  • 6.3.14 Randox Laboratories Ltd.
  • 6.3.15 Quanterix Corporation
  • 6.3.16 Creative Diagnostics
  • 6.3.17 LabCorp
  • 6.3.18 Quest Diagnostics Incorporated

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment